Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aligos Therapeutics (ALGS) Other Non-Current Assets (2020 - 2025)

Aligos Therapeutics filings provide 6 years of Other Non-Current Assets readings, the most recent being $715000.0 for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 14.04% to $715000.0 in Q4 2025 year-over-year; TTM through Dec 2025 was $715000.0, a 14.04% increase, with the full-year FY2025 number at $715000.0, up 14.04% from a year prior.
  • Other Non-Current Assets hit $715000.0 in Q4 2025 for Aligos Therapeutics, roughly flat from $713000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $1.6 million in Q1 2022 to a low of $21000.0 in Q2 2022.
  • Median Other Non-Current Assets over the past 5 years was $626000.0 (2024), compared with a mean of $490100.0.
  • Biggest five-year swings in Other Non-Current Assets: tumbled 89.12% in 2022 and later skyrocketed 814.29% in 2025.
  • Aligos Therapeutics' Other Non-Current Assets stood at $866000.0 in 2021, then decreased by 26.79% to $634000.0 in 2022, then crashed by 88.96% to $70000.0 in 2023, then skyrocketed by 795.71% to $627000.0 in 2024, then grew by 14.04% to $715000.0 in 2025.
  • The last three reported values for Other Non-Current Assets were $715000.0 (Q4 2025), $713000.0 (Q3 2025), and $640000.0 (Q2 2025) per Business Quant data.